Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07818798) titled 'Proton and Proton-Photon Hybrid Partial Stereotactic Ablative Boost Radiotherapy (P-SABR) for Unresectable Large Tumors' on Sept. 3.

Study Type: Observational

Primary Sponsor: Peking University First Hospital

Condition: Unresectable Malignant Neoplasm Bulky Tumor Solid Tumor

Intervention: Radiation: Proton P-SABR

Recruitment Status: Not recruiting

Date of First Enrollment: October 2026

Target Sample Size: 60

To know more, visit https://clinicaltrials.gov/study/NCT07818798

Published by HT Digital Content Services with permission from Health Daily Digest....